IGF-1 and survival in ESRD

What Was Tested

The paper reports a study of IGF-1 LR3, published as a observational study.

IGF-1 deficiency links to malnutrition in CKD patients; however, it is not clear to what extent it associates with survival among these patients.

Who Took Part

The study group was 5 patients.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Serum IGF-1 and other biochemical, clinical (subjective global assessment), and densitometric (dual energy x-ray absorptiometry) markers of nutritional status and mineral and bone metabolism were measured in a cohort of 365 Swedish clinically stable CKD stage 5 patients (median age of 53 years) initiating dialysis between 1994 and 2009; in 207 patients, measurements were also taken after 1 year of dialysis.

How the Study Was Run

The methods mention a period of 1 year.

Associations of mortality with baseline IGF-1 and changes of IGF-1 after 1 year of dialysis were evaluated by Cox models.

What Was Measured

The subject headings attached to it are Biomarkers, Body Composition, Bone Remodeling, Chi-Square Distribution, Cross-Sectional Studies, Down-Regulation and Insulin-Like Growth Factor I.

What This Means in Plain Language

This is a observational study of IGF-1 LR3 in 5 patients over 1 year.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (Clinical journal of the American Society of Nephrology : CJASN), a journal based in United States.

More context: the IGF-1 LR3 compound page, all human trials.